Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), also known as Arrhythmogenic Right Ventricular Dysplasia (ARVD), is an inherited heart muscle disorder characterized by the progressive replacement of right ventricular myocardium with fibro-fatty tissue. This structural remodeling creates an electrically unstable substrate prone to life-threatening ventricular arrhythmias, making ARVC one of the leading causes of sudden cardiac death (SCD) in young people and athletes. Estimated to affect approximately 1 in 2,000 to 5,000 individuals, the condition is caused predominantly by mutations in desmosomal proteins that anchor cardiomyocytes together. Early recognition, genetic testing, exercise restriction, and appropriate use of implantable defibrillators are central to management and survival.

Table of Contents

  1. Overview
  2. Genetics and Pathophysiology
  3. Clinical Presentation
  4. Electrocardiographic Findings
  5. Diagnostic Criteria (2010 Task Force)
  6. Treatment
  7. Risk Stratification and Prevention
  8. Prognosis
  9. Recent Research and Advances
  10. References
  11. Connections
  12. Featured Videos

Overview

Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a primary myocardial disease that predominantly affects the right ventricle, though biventricular and left-dominant forms are increasingly recognized. The fundamental pathological process is the gradual replacement of normal heart muscle — cardiomyocytes — with fibrous and adipose tissue. This fibro-fatty infiltration disrupts the organized electrical conduction pathways of the heart, creating zones of slow conduction and reentry circuits that sustain potentially fatal ventricular arrhythmias.

The disease was formally described in 1982 by Marcus and colleagues, who identified its hallmark features of right ventricular structural abnormalities combined with ventricular tachycardia of left bundle branch block (LBBB) morphology. The term "dysplasia" in the older name ARVD reflects the earlier (and now largely abandoned) hypothesis that fibro-fatty replacement represented a developmental defect. Current understanding recognizes the condition as a progressive, genetically determined cardiomyopathy driven by desmosomal dysfunction.

The fibro-fatty replacement in ARVC tends to concentrate in three anatomical regions collectively called the triangle of dysplasia: the right ventricular outflow tract (RVOT), the right ventricular apex, and the subtricuspid (inferior/diaphragmatic) region. These areas are preferential sites for arrhythmia origin and structural wall motion abnormalities detectable by imaging.

The prevalence is estimated at 1 in 2,000 to 1 in 5,000 in the general population, though this is likely an underestimate given the highly variable disease penetrance (approximately 30–50% of mutation carriers show clinical manifestations) and the fact that sudden death may be the first presentation. ARVC accounts for up to 17% of sudden cardiac deaths in young people under age 35 in some populations, and for an even higher proportion in athletes, particularly in regions of Italy where the condition has been extensively studied.

Back to Table of Contents

Genetics and Pathophysiology

ARVC is a genetic disease with autosomal dominant inheritance in the vast majority of cases, although rare autosomal recessive syndromes exist. The molecular basis centers on mutations affecting the cardiac desmosome — the protein complex that mechanically couples adjacent cardiomyocytes and anchors the cytoskeleton at cell-cell junctions.

The five major desmosomal proteins implicated in ARVC are:

Non-desmosomal genes implicated include TMEM43 (a transmembrane protein associated with aggressive ARVC in Newfoundland populations), LMNA, SCN5A, PLN (phospholamban), CDH2, and RYR2. Variants in non-desmosomal genes account for a smaller fraction of cases but can present with overlapping phenotypes including dilated cardiomyopathy.

The pathophysiological cascade from desmosomal mutation to fibro-fatty cardiomyopathy is not completely understood, but two major mechanisms are proposed. The mechanical hypothesis holds that impaired cell-cell adhesion leads to cardiomyocyte detachment and death under the mechanical stress of repeated cardiac contraction, with subsequent replacement by fibrofatty scar. The signaling hypothesis proposes that disruption of the desmosome causes mislocalization of junctional plakoglobin (gamma-catenin) to the nucleus, where it competitively inhibits Wnt/beta-catenin signaling, promoting adipogenesis of cardiac progenitor cells. Both mechanisms likely operate in tandem.

Exercise plays a critical accelerating role: endurance training markedly increases right ventricular wall stress and accelerates fibrofatty replacement, explaining why ARVC manifests earlier and more severely in competitive athletes compared to sedentary mutation carriers.

Naxos disease is a rare autosomal recessive syndrome caused by homozygous mutations in JUP, presenting as a triad of ARVC, palmoplantar keratoderma (thickening of palm and sole skin), and woolly hair. It was first described on the Greek island of Naxos.

Carvajal syndrome is caused by recessive mutations in DSP and presents with a similar triad but with predominant left ventricular involvement rather than classical right-dominant ARVC, along with dilated cardiomyopathy features.

Back to Table of Contents

Clinical Presentation

ARVC typically presents in the second through fourth decades of life, though the age of onset is variable and influenced by genotype, sex, and physical activity level. Men are more commonly and more severely affected than women, even among carriers of the same mutation. The disease is rarely manifest in children under 12 years of age.

Clinical presentations exist on a spectrum from asymptomatic ECG or imaging abnormalities discovered incidentally, to symptomatic arrhythmias, to sudden cardiac arrest as the first manifestation. The classic clinical scenario is a young athlete presenting with palpitations, presyncope, or syncope during or immediately after exercise. The exertional triggering pattern distinguishes ARVC from many other channelopathies such as Long QT syndrome, which is more commonly triggered by emotion or sudden auditory stimuli.

Four clinical phases are recognized:

  1. Concealed phase: Structural and electrical abnormalities are absent or subtle; sudden death can still occur, particularly with intense exertion, making this phase particularly dangerous for competitive athletes who are unaware of their diagnosis.
  2. Overt electrical phase: Symptomatic ventricular arrhythmias (palpitations, presyncope, syncope) emerge; typical LBBB-morphology VT indicates origin in the right ventricle. Structural abnormalities are detectable on imaging in most patients at this stage.
  3. Structural RV disease: Progressive fibro-fatty replacement produces right ventricular dilation and global dysfunction. Symptoms of right heart failure may appear — exercise intolerance, leg edema, elevated jugular venous pressure.
  4. Biventricular failure: In a subset (approximately 10–15%) the disease extends to the left ventricle, producing a picture closely resembling dilated cardiomyopathy with biventricular systolic dysfunction and advanced heart failure requiring transplantation.

Family history of unexplained sudden cardiac death in a young family member, or a family member with documented ARVC or desmosomal mutation, raises clinical suspicion substantially. Because disease penetrance is 30–50%, first-degree relatives of an index case require systematic screening even in the absence of symptoms.

Back to Table of Contents

Electrocardiographic Findings

The 12-lead ECG is the single most accessible diagnostic tool in ARVC and shows a characteristic constellation of repolarization and depolarization abnormalities reflecting fibro-fatty replacement of right ventricular myocardium.

Epsilon wave: The most specific ECG finding in ARVC is the epsilon wave — a small, distinct positive deflection that appears in the terminal portion of the QRS complex in leads V1–V3, representing delayed activation of islands of surviving myocardium within the fibrosed right ventricle. It is best seen with signal-averaged ECG but is visible on standard 12-lead ECG in approximately 30% of affected patients. The epsilon wave is considered pathognomonic of ARVC when unequivocally present.

T-wave inversions in V1–V3: Inverted T-waves across the right precordial leads (V1 through at least V3) in the absence of right bundle branch block are a major ECG criterion for ARVC in patients over 14 years of age. This repolarization abnormality reflects the altered electrical properties of fibro-fatty-replaced myocardium and is present in over 80% of symptomatic patients. T-wave inversions that extend to V4, V5, or V6 suggest more extensive disease or left ventricular involvement (particularly DSP mutations).

Right bundle branch block (RBBB): Complete or incomplete RBBB may develop as fibro-fatty infiltration disrupts the right bundle branch conduction axis. When RBBB is present and T-waves are inverted in V1–V3, this is attributed to the RBBB itself and does not count as an independent criterion.

Prolonged S-wave upstroke (terminal activation delay): A terminal activation delay defined as ≥55 ms measured from the nadir of the S-wave to the end of all depolarization in V1, V2, or V3 (in the absence of complete RBBB) is a minor ECG criterion.

Ventricular tachycardia morphology: VT in ARVC characteristically shows LBBB morphology because it originates in the right ventricle. The most common form arises from the RVOT and has an inferior axis (positive QRS in leads II, III, and aVF), reflecting superior-to-inferior activation. VT arising from the subtricuspid region tends to have a superior axis. Incessant monomorphic VT, multiple VT morphologies (indicating multiple scar-based reentry circuits), and non-sustained runs are all well-recognized presentations.

Signal-averaged ECG (SAECG): SAECG can detect late potentials — low-amplitude, high-frequency signals at the end of the QRS representing slow conduction through scarred myocardium. Abnormal SAECG meeting two of three criteria (filtered QRS duration >114 ms, duration of terminal QRS <40 µV signal >38 ms, root mean square voltage of terminal 40 ms <20 µV) constitutes a minor Task Force criterion.

Back to Table of Contents

Diagnostic Criteria (2010 Task Force)

The diagnosis of ARVC is formalized through the revised 2010 Task Force Criteria (TFC), which replaced the original 1994 criteria with more precise quantitative thresholds to improve both sensitivity and specificity. The revised criteria are organized into six categories, each with major and minor criteria. A definitive diagnosis requires 2 major criteria, or 1 major + 2 minor criteria, or 4 minor criteria from different categories. A borderline diagnosis is made with 1 major + 1 minor, or 3 minor from different categories. Possible ARVC is 1 major or 2 minor criteria.

Category I: Structural and Functional Abnormalities by Echocardiography, Cardiac MRI, or Angiography

Major: Regional RV akinesia, dyskinesia, or aneurysm plus one of the following — RV outflow tract parasternal long-axis dimension ≥32 mm (PLAX/BSA ≥19 mm/m²), PLAX short-axis ≥36 mm (PSAX/BSA ≥21 mm/m²), or fractional area change ≤33%.
Minor: Less severe wall motion abnormality with borderline dimensions.

Category II: Tissue Characterization of Walls (Endomyocardial Biopsy)

Major: Residual myocytes <60% by morphometric analysis with fibrous replacement on ≥1 sample (with or without fatty replacement of RV free wall on endomyocardial biopsy).
Minor: Residual myocytes 60–75% with fibrous replacement.

Category III: Repolarization Abnormalities (ECG)

Major: Inverted T-waves in V1–V3 in patients >14 years, without RBBB.
Minor: Inverted T-waves in V1–V2 in patients >14 years without RBBB, or in V4–V6; inverted T-waves in V1–V4 with complete RBBB.

Category IV: Depolarization and Conduction Abnormalities (ECG)

Major: Epsilon wave in V1–V3.
Minor: SAECG late potentials (any of 3 criteria without RBBB); QRS ≥110 ms in V1–V3 without complete RBBB; terminal activation delay ≥55 ms in V1, V2, or V3 without RBBB.

Category V: Arrhythmias

Major: Non-sustained or sustained VT with LBBB morphology and superior axis (negative or indeterminate QRS in leads II, III, aVF).
Minor: Non-sustained or sustained VT with RVOT morphology (LBBB, inferior axis); more than 500 PVCs in 24 hours on Holter monitoring.

Category VI: Family History

Major: ARVC confirmed in first-degree relative meeting current TFC; ARVC confirmed at autopsy or surgery in first-degree relative; identification of a pathogenic mutation categorized as disease-causing in the patient.
Minor: ARVC history in first-degree relative where it is not possible to determine whether family member meets current TFC; premature sudden death (<35 years) due to suspected ARVC in first-degree relative; ARVC confirmed in second-degree relative.

Cardiac MRI plays an especially important role in modern ARVC evaluation. It can detect RV free wall motion abnormalities and RV dilation with high precision, and late gadolinium enhancement (LGE) identifies fibrous replacement — a finding that has prognostic implications beyond the structural TFC criteria. Fat infiltration on MRI (high signal on T1-weighted sequences) is a recognized feature, though it requires careful interpretation because physiological epicardial fat is common in the normal RV.

Back to Table of Contents

Treatment

Management of ARVC is individualized based on the patient's arrhythmia burden, risk of sudden cardiac death, degree of structural heart disease, and degree of functional impairment. No treatment has been shown to prevent the underlying fibro-fatty progression, so current therapies target arrhythmia suppression and SCD prevention.

Exercise Restriction

Exercise restriction is arguably the single most impactful intervention available for ARVC. Competitive sports and high-intensity endurance activities are prohibited for all patients with a definite diagnosis of ARVC, regardless of symptoms. Because intense exercise accelerates fibro-fatty replacement and markedly increases arrhythmia risk — including in the concealed phase — exercise restriction is also recommended for first-degree relatives who carry a pathogenic mutation, even before they meet diagnostic criteria. Low-intensity recreational activity (walking, light yoga) is generally permitted with guidance from a specialist.

Implantable Cardioverter-Defibrillator (ICD)

ICD implantation is the most effective therapy for preventing sudden death. Class I indications include:

ICD therapy carries specific complications in ARVC including inappropriate shocks (from T-wave oversensing due to RV electrode displacement as the RV dilates and deforms), lead failure from chronic RV structural changes, and the psychological burden on young patients. Subcutaneous ICDs (S-ICD) are an option for patients without pacing or resynchronization needs, avoiding intravascular leads. Wearable cardioverter-defibrillators (WCD) may bridge patients to ICD implantation or cover acute high-risk periods.

Antiarrhythmic Drug Therapy

Sotalol is the most commonly used antiarrhythmic agent for ARVC, combining beta-blockade with class III potassium channel blockade. It reduces VT frequency and is used in combination with ICD therapy to decrease shock burden. Amiodarone is effective but reserved for patients with refractory arrhythmias given its cumulative organ toxicity (thyroid, pulmonary, hepatic). Beta-blockers alone (metoprolol, bisoprolol) provide modest VT suppression but are insufficient as monotherapy for sustained VT. Class IC agents (flecainide, propafenone) are generally avoided in structurally abnormal hearts due to proarrhythmic risk.

Catheter Ablation

Catheter ablation is used for VT refractory to or intolerant of antiarrhythmic drugs, or as an adjunct to ICD therapy in patients with frequent appropriate shocks ("VT storm"). Because the critical circuits in ARVC are located in the epicardium (on the outer surface of the RV free wall) as well as the endocardium, combined endocardial-epicardial mapping and ablation through subxiphoid pericardial access achieves substantially better outcomes than endocardial-only ablation. Electroanatomic mapping delineates low-voltage scar borders to guide substrate ablation. Recurrence after ablation is common (30–50% at 3 years) as the underlying disease continues to progress.

Heart Failure Therapy and Transplantation

Patients with biventricular dysfunction receive standard heart failure pharmacotherapy (ACE inhibitors/ARBs, beta-blockers, diuretics). In advanced end-stage disease with refractory heart failure or intractable arrhythmias unresponsive to all other therapies, cardiac transplantation provides definitive cure — both the structural cardiomyopathy and the arrhythmia substrate are eliminated.

Back to Table of Contents

Risk Stratification and Prevention

Identifying which ARVC patients are at highest risk of sudden cardiac death is a critical clinical challenge. Unlike hypertrophic cardiomyopathy, where validated scoring tools exist (HCM Risk-SCD), risk stratification in ARVC remains incompletely standardized. Multiple clinical variables have been identified as predictors of adverse events:

Family screening is a cornerstone of ARVC prevention. All first-degree relatives (parents, siblings, children) of a confirmed case should undergo:

  1. 12-lead ECG
  2. 24-hour Holter monitoring
  3. Echocardiography
  4. Signal-averaged ECG
  5. Genetic testing for the family's specific mutation (if identified)
  6. Cardiac MRI (if any findings are abnormal or equivocal)
  7. Exercise stress testing in selected cases

Relatives found to carry a pathogenic mutation but who do not yet meet diagnostic criteria are advised to restrict exercise and undergo clinical surveillance every 1–3 years, as penetrance is incomplete and disease can manifest over time.

Back to Table of Contents

Prognosis

The prognosis of ARVC is highly variable, ranging from a benign course with minimal symptoms across decades to sudden death at a young age. Disease penetrance of approximately 30–50% means that many gene carriers never develop clinically significant manifestations. However, once the condition is clinically manifest, its trajectory depends heavily on the arrhythmia burden, degree of structural involvement, and adherence to exercise restriction and therapy.

In ICD recipients, the annual rate of appropriate ICD shock (evidence of a treated life-threatening arrhythmia) ranges from approximately 9–17% per year in high-risk populations, underscoring the ongoing arrhythmia burden even in treated patients. Long-term follow-up studies suggest that overall mortality with modern ICD therapy is relatively low (around 1–2% per year), but quality of life can be impaired by frequent ICD interventions, antiarrhythmic drug side effects, and psychological burden.

Heart failure as a cause of death or transplantation is less common than arrhythmic death but affects approximately 10–20% of patients followed over decades, particularly those with biventricular involvement. The 10-year transplant-free survival in unselected ARVC populations is approximately 70–80% in contemporary cohorts managed with ICD.

Genotype has prognostic implications. PKP2 mutations are generally associated with classical right-dominant ARVC and intermediate penetrance. DSP mutations carry a higher risk of LV involvement, severe ventricular dysfunction, and early heart failure. TMEM43 mutations (especially the p.S358L variant in Newfoundland founder populations) carry very high rates of SCD and heart failure, with male carriers having near-universal lethal events before age 50 without ICD therapy.

Exercise restriction remains the most modifiable prognostic factor in the long term. Registry data consistently demonstrate that patients who continue competitive sports have substantially worse outcomes than those who comply with activity restriction, even when controlling for baseline disease severity.

Back to Table of Contents

Recent Research and Advances

ARVC research has advanced substantially over the past decade, spanning molecular mechanisms, improved imaging, novel risk stratification tools, and emerging therapies.

Desmosome biology and Wnt signaling: The discovery that desmosomal disruption suppresses Wnt/beta-catenin signaling — promoting adipogenesis of cardiac progenitor cells — has opened therapeutic avenues. Preclinical models using GSK-3 inhibitors and other Wnt activators have shown reduction in fibro-fatty replacement, though none are yet in clinical trials for ARVC specifically.

Improved MRI protocols: Advances in cardiac MRI including phase-sensitive inversion recovery for late gadolinium enhancement and 4D flow sequences have improved both sensitivity and specificity for early ARVC detection. Strain imaging by feature tracking MRI can detect subtle RV wall motion abnormalities meeting Task Force criteria even before overt dysfunction. LGE extent on MRI has emerged as an independent predictor of VT recurrence after catheter ablation.

Risk stratification scores: The ARVC risk calculator (developed from the multinational ARVC registry — arvc.ca) provides individualized 5-year risk estimates for a composite arrhythmic endpoint, incorporating clinical variables including prior VT history, syncope, NSVT, SAECG results, RV dimensions, and sex. This tool is increasingly used to guide ICD implantation decisions in intermediate-risk patients.

Precision catheter ablation: Combined endocardial-epicardial ablation guided by high-density electroanatomic mapping (CARTO, Rhythmia) has improved acute success and reduced recurrence rates compared to historical endocardial-only ablation. Ablation of low-voltage scar borders rather than only VT isthmuses (substrate ablation) appears more durable. Centers reporting combined approaches document VT-free survival of 60–75% at 3 years.

Left-dominant ARVC: Recognition of left-dominant and biventricular ARVC variants — where the LV is primarily or equally affected — has expanded the diagnostic concept. These cases, often linked to DSP mutations, may mimic myocarditis or dilated cardiomyopathy and require MRI and genetic testing for correct diagnosis.

Exercise studies and mechanisms: Longitudinal exercise studies in mouse models and in human athletes have confirmed that endurance exercise accelerates desmosomal damage and fibro-fatty replacement in PKP2 heterozygotes. These findings reinforce the clinical recommendation for activity restriction and have generated interest in whether supervised low-intensity exercise can be individualized rather than universally prohibited.

Gene therapy and RNA approaches: Early-phase work in cardiomyocyte culture and animal models has explored exon-skipping strategies for certain PKP2 variants and antisense oligonucleotide approaches to upregulate residual PKP2 expression in haploinsufficiency, but clinical application remains years away.

Back to Table of Contents

References

  1. Marcus FI, Fontaine GH, Guiraudon G, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982;65(2):384–398. PMID 7053899
  2. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J. 2010;31(7):806–814. PMID 20172912
  3. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997;30(6):1512–1520. PMID 9362410
  4. Dalal D, Molin LH, Piccini J, et al. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation. 2006;113(13):1641–1649. PMID 16567567
  5. Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet. 2004;36(11):1162–1164. PMID 15489854
  6. Kirchhof P, Fabritz L, Zwiener M, et al. Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation. 2006;114(17):1799–1806. PMID 17030680
  7. James CA, Bhonsale A, Tichnell C, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62(14):1290–1297. PMID 23871885
  8. Bhonsale A, James CA, Tichnell C, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol. 2011;58(14):1485–1496. PMID 21939833
  9. Corrado D, Wichter T, Link MS, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Circulation. 2015;132(5):441–453. PMID 26216213
  10. Berruezo A, Fernandez-Armenta J, Mont L, et al. Combined endocardial and epicardial catheter ablation in arrhythmogenic right ventricular dysplasia incorporating scar dechanneling technique. Circ Arrhythm Electrophysiol. 2012;5(1):111–121. PMID 22062796
  11. Orgeron GM, James CA, Te Riele A, et al. Implantable cardioverter-defibrillator performance in plakophilin-2 (PKP2) arrhythmogenic right ventricular dysplasia/cardiomyopathy: a multivariable prediction model. Circ Arrhythm Electrophysiol. 2014;7(5):818–825. PMID 25161019
  12. Protonotarios N, Tsatsopoulou A. Naxos disease and Carvajal syndrome: cardiocutaneous disorders that highlight the pathogenesis and broaden the spectrum of arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Pathol. 2004;13(4):185–194. PMID 15210133

Back to Table of Contents

Connections

Back to Table of Contents